IDH1 and central nervous system cancer: Alternatively, the presence of glioblastoma can only be identified in plasma DNA in less than 10% of patients while analyzing a plethora of point mutations and genomic rearrangements8 and in 60% of IDH1 mutant glioma patients when specifically analyzing IDH1 mutants.9